Skip to main content
Top
Published in:

04-07-2024 | Polyneuropathy | Case Report

Atypical presentations in an RTD patient and report of novel SLC52A3 and SLC52A2 mutations

Authors: Donya Sabeghi, Kolsoum InanlooRahatloo, Hanieh S. Mirzadeh, Marzieh Khani, Hosein Shamshiri, Tarannomsadat Taghavi, Afagh Alavi, Reza Boostani, Seyed Hassan Tonekaboni, Javad Akhondian, Masoomah Ebrahimi, Najmeh Salehi, Shahriar Nafissi, Elahe Elahi

Published in: Acta Neurologica Belgica | Issue 4/2024

Login to get access

Abstract

Introduction

Riboflavin Transporter Deficiency (RTD) is a rare neurological disorder characterized by pontobulbar palsy, hearing loss, and motor cranial nerve involvement. SLC52A3 and SLC52A2 mutations are causes of RTD. SLC52A2 mutations are usually found in childhood onset cases. Fifteen Iranian RTD diagnosed patients without SLC52A2 mutations have been previously described. We aimed to identify causative mutations in two childhood cases.

Methods

We recruited patients with diagnosis of BVVL. Comprehensive clinical evaluations were performed on the patients. SLC52A3 and SLC52A2 genes were PCR-amplified and Sanger sequenced. Candidate disease causing variations were screened for segregation with disease status in the respective families and control individuals.

Results

A novel homozygous SLC52A3 mutation (p.Met1Val) and a heterozygous SLC52A2 mutation (p.Ala288Val) were both observed in one proband with typical RTD presentations. The aggregate of presentations in the early stages of disease in the second patient that included weakness in the lower extremities, absence of bulbar or hearing defects, prominent sensory polyneuropathy as evidenced in electrodiagnostic studies, and absence of sensory symptoms including sensory ataxia did not prompt immediate RTD diagnosis. Dysarthria and decreased hearing manifested later in the disease course. A novel homozygous SLC52A2 (p.Val314Met) mutation was identified.

Conclusion

A literature search found recent reports of other atypical RTD presentations. These include MRI findings, speech understanding difficulties accompanied by normal hearing, anemia, and left ventricular non-compaction. Knowledge of unusual presentations lessens the chance of misdiagnosis or delayed RTD diagnosis which, in light of favorable effects of riboflavin supplementation, is of immense importance.
Appendix
This content is only visible if you are logged in and have the appropriate permissions.
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
Atypical presentations in an RTD patient and report of novel SLC52A3 and SLC52A2 mutations
Authors
Donya Sabeghi
Kolsoum InanlooRahatloo
Hanieh S. Mirzadeh
Marzieh Khani
Hosein Shamshiri
Tarannomsadat Taghavi
Afagh Alavi
Reza Boostani
Seyed Hassan Tonekaboni
Javad Akhondian
Masoomah Ebrahimi
Najmeh Salehi
Shahriar Nafissi
Elahe Elahi
Publication date
04-07-2024
Publisher
Springer International Publishing
Published in
Acta Neurologica Belgica / Issue 4/2024
Print ISSN: 0300-9009
Electronic ISSN: 2240-2993
DOI
https://doi.org/10.1007/s13760-024-02598-7

How can your team use biomarkers to improve management of AD? (Link opens in a new window)

Our experts explore using biomarker tests and interpreting results, establishing a shared decision-making approach with patients and caregivers, and applying biomarker testing to guide treatment strategies.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Healthcare IME
Register your interest

How can you integrate PET into your practice? (Link opens in a new window)

1.5 AMA PRA Category 1 Credit(s)™

PET imaging is playing an increasingly critical role in managing AD. Our expert-led program will empower you with practical strategies and real-world case studies to effectively integrate it into clinical practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Healthcare IME
Register your interest